



## Overview of the PAHO Strategic Fund and its benefits

February 2017

**Analía Porrás, MD. Ph.D.**

Unit Chief

Medicines and Health Technologies, HSS/MT

PAHO/WHO

## Access to medicines

- The lack of access to safe, efficacious and quality medicines and other health technologies is a persistent problem in the Region, in particular, those considered High Cost
- Availability of certain low cost medicines is also at risk since they are being replaced with new, more expensive ones of little additional value
- Price, quality and availability are issues that the SF can help address and improve access in MS. However, we need to ensure that other barriers to access are not impeding effective access to medicines



# Regional Strategy on Universal Access to Health & Universal Health Coverage (2014)

- **Four Strategic Lines of Action;**

**Progressively expanding access to quality, integrated and comprehensive health services**

**Strengthening governance and stewardship**

**Increased and more efficient public financing in health**

**Addressing the social determinants of health**



# Increased Awareness on Pricing and Sustainability

BUSINESS DAY

## Senators Condemn Big Price Increases for Drugs

By ANDREW POLLACK DEC. 9, 2015

Senators from both parties on Wednesday denounced huge overnight price increases for decades-old drugs that have been made by some pharmaceutical companies lately, calling them unconscionable and detrimental to patients.

El País.com.co



17



0



Tratar el cáncer, el sida, la artritis, el reumatismo o la hemofilia en adelante no será tan caro como lo ha sido hasta hoy. La razón es que muchos de los medicamentos necesarios para su tratamiento y que tienen costos exorbitantes serán sometidos a control y reducirán su precio dos, tres y más veces desde el próximo mes.

Eso significa que los más de cuatro millones de colombianos que hoy no

## OCDE advierte que alto precio de medicamentos está afectando los presupuestos de salud

Por Kate Kelland  
Reuters  
4 de noviembre de 2015

Por Kate Kelland

LONDRES (Reuters) - El alto precio de los medicamentos de especialidad que cobran las empresas farmacéuticas está afectando los presupuestos de salud de las naciones ricas, dijo la OCDE el miércoles, ya que los fármacos representan cerca del 20 por ciento de todo el gasto en salud.

En los 33 países de la OCDE, el gasto farmacéutico alcanzó los 800.000 millones de



# PAHO Strategic Fund

2000 → 2016





## SF: Signatory Members

30 Member states and Territories



# Added Value of the Strategic Fund



**Technical Cooperation to improve demand planning and selection of strategic health supplies for health programs**

Evidence based processes linked to treatment guidelines and expansion of health programs

**Cooperation on Supply Chain Management**

Improve planning, procurement, distribution and sustainability of core supply chain processes

**Assure Quality of Commodities**

International standards for selection and evaluation of products and suppliers

**Strategic Fund Capital Account**

Support instant actions to ensure continuous supply and avoid product shortages

**Improved access to strategic public health supplies**

Strategic purchases related to programmatic actions leading to improved access



# The PAHO Revolving Funds

## Benefits for Stakeholders


### For Countries

- Technical cooperation mechanism
- Timely and continuous supply
- Safe, quality products
- Supports financial sustainability
- “Catalyst” for a sustainable uptake of new products
- Access to a credit line (60 days)


### For Manufacturers

- Direct access to 41 countries and territories
- Mechanisms to support technical programs and enforce robust health systems
- Post-marketing surveillance
- Reliable forecasts and transparent relations
- Long Term Agreements
- Prompt payments





## SF: types of commodities and criteria for selection



## SF Perspectives

- PAHO/SF is an important mechanism to ensure access to strategic health supplies in the Americas to support UA/UHC
- Effective procurement of all types of medicines defined by:
  - Availability
  - Price
  - Quality
- Added value beyond purchase: **Technical cooperation** in quality assurance, supply chain, demand forecasting and planning, rational use.
- Improve pharmaceutical market dynamics for the Americas: transparency, elimination of spurious incentives

# Opportunities

- Which are the priorities?
- Which are the opportunities for strengthening joint work?
- How to work together PAHO and countries?
  - capitalization account
  - quality perspective



# Challenges

- **Barriers to consolidate demand**
  - Low capacities for demand forecasting and supply chain management at country level; lack of proper health information systems at national level
  - Patents and other IP related issues
  - Tiered pricing and sole source products
- **Products of that are difficult to procure**
  - Sole or limited source products
  - Small volumes
  - Controlled substances